MLchartDataset catalogue

dacliximab

Term · Oncology and biomedicine · MLC-T-ONC-002265

A drug used to keep the body from rejecting kidney transplants. It is also being studied in the treatment of some types of cancer and other conditions. Dacliximab binds to receptors for a protein called interleukin-2, which are found on some types of immune cells and cancer cells. This may help suppress the body’s immune response and it may help kill cancer cells. Dacliximab is a type of monoclonal antibody. Also called daclizumab and Zenapax.

Table 1. Record
IdentifierMLC-T-ONC-002265
FieldOncology and biomedicine
Synonymsdaclizumab; Zenapax
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-002265",
  "term": "dacliximab",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to keep the body from rejecting kidney transplants. It is also being studied in the treatment of some types of cancer and other conditions. Dacliximab binds to receptors for a protein called interleukin-2, which are found on some types of immune cells and cancer cells. This may help suppress the body’s immune response and it may help kill cancer cells. Dacliximab is a type of monoclonal antibody. Also called daclizumab and Zenapax.",
  "synonyms": [
    "daclizumab",
    "Zenapax"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/dacliximab/"
}

Record 5,654 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.